inPractice® - Antiarrhythmics

Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care

Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
Section Editor: Eric S. Daar, MD
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 6/1/18 (What's New)

Summary

Potential for antiarrhythmics to interact with all antiretrovirals; therefore, caution should be used upon coadministration
Antiarrhythmics (eg, disopyramide, dofetilide, lidocaine, mexiletine, and propafenone) should not be coadministered with any ritonavir-boosted or cobicistat-boosted PI^{[DHHS ART]}
- If unboosted atazanavir is coadministered, monitor for antiarrhythmic-related adverse events

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Drug-Drug Interactions, Pharmacokinetics